NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Attovia Therapeutics, Inc. (ATTO) Stock Analysis

Attovia Therapeutics, Inc. (ATTO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ATTO

$14.18

+$0.14 (+1.00%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ATTO with… →

ATTO Key Statistics

As of Oct 21, 2026
Trading
Open
$14.02
Previous Close
$14.04
Day's Range
13.98–15.07
52-Week Range
12.94–28.00
Volume
279.89K
Valuation
Market Cap
$647.33M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
359.63
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.74
Financials (FY)
Revenue (FY)
$1.35M
Net Income (FY)
−$60.63M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
45.65M
Dividend and dates
Earnings Date
November 11, 2026estimated
Avg Volume
455.92K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

Attovia Therapeutics, Inc. (ATTO) has a market capitalization of $647.33M.

In fiscal 2025, ATTO reported revenue of $1.35M.

ATTO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.35M−$60.63M−4,490.9%
2024$0.00−$39.80M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.35M—−$67.16M−$60.63M−4,490.9%
2024$0.00—−$41.55M−$39.80M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ATTO Valuation vs Biotechnology Median

Median of 608 stocks
MetricATTOBiotechnology medianvs median
P/S ratio359.6313.3027.0x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 13 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Attovia Therapeutics, Inc. (ATTO) is capitalised at $647.33M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 44 employees.

The 52-week range on file runs from $12.94 to $28.00. The most recent close on file for ATTO is $14.18, dated October 21, 2026. That is +$0.14 (+1.00%) against the previous close. The latest close sits 9.58% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $1.35M. The same year closed with a net loss of $60.63M. Trailing earnings per share are −2.74.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 359.63. On price-to-sales that is 27 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Growth & Income

The record shows no dividend for ATTO.

So far in 2026 the total return is −35.25%.

Peer Comparison

Attovia Therapeutics, Inc. (ATTO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Attovia Therapeutics, Inc. ATTO $647.33M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Attovia Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Attovia Therapeutics, Inc.

Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobulin G (IgG)-fusion protein therapeutic that inhibits IL-13 and IL-31; developed for the treatment of AD and other immune-mediated skin diseases, such as CSU and PN; and ATTO-1091, a trispecific ATTOBODY-based Fc-fusion protein therapeutic that inhibits TL1A, IL-23, and integrin a4ß7; developed for IBD a chronic immune-mediated condition characterized by persistent inflammation of the gastrointestinal tract, includes ulcerative colitis (UC) and crohn's disease (CD). The company was incorporated in 2022 and is based in San Carlos, California.

Visit website →